“There is exciting science happening throughout Asia, and enormous potential for leadership in innovative drug discovery,” announced the CEO of Atomwise, Dr. Abraham Heifets. “I am delighted to announce that Hansoh Pharma is our first partner in Asia. Hansoh Pharma is committed to innovation and shares our mission for global impact on patient’s health.” he added.
Atomwise is one of the leading organization that focuses on the use of Artificial Intelligence for drug discovery, specifically the small molecule drug discovery. The organization is a known partner with some of the leading pharmaceutical and agrochemical companies in the world.
The partnership between these two organization, which is known as the largest China- US collaboration for AI drug discovery, will require a close working relationship between both firm’s scientific teams in a bid to achieve their aim of increasing the success rate of drug delivery while also reducing the time required to achieve this delivery.
The conditions for this partnership will include Atomwise getting up to $1.5 million for the development of first in- class and best in- class small molecules. This fee to be received is an accumulation of fees such as technology access fees, option exercise fees, royalties and many other sub-fees. The target of this collaboration will include about eleven target proteins in multiple therapeutic areas.
“Atomwise is the right partner for Hansoh Pharma to innovate using AI technology and generate a diverse pipeline of small molecules for oncology and other therapeutic areas, said Aifeng Lyu, Ph.D, president of Jiangsu Hansoh Pharmaceutical Group Co.,Ltd., a subsidiary of Hansoh Pharma. “We have been very impressed by Atomwise’s AI platform, capabilities, and team, and by working together we believe there are exceptional opportunities to develop first in- class and best in- class therapies.”
Hansoh Pharma is a known China- based pharmaceutical company that discovers and creates new forms of drugs that can help patients fight against life- threatening medical conditions. The 8,900- employee company is rated as one of the top 2 highly innovative companies in the biotech and pharmaceutical industry for China.